In this MEDtalk professor Stefan Schreiber present a head-to-head study of the efficacy and safety of vedolizumab and adalimumab for treatment over 52 weeks in adults with moderately to severely active ulcerative colitis (UC). The first study to directly compare two biological agents in IBD. Click and hear the results.
MEST SETE MEDtalks
ECCO 2019: Prevalence and healthcare costs of perianal fistulas in Crohn’s disease Se hele webinar
Thiopurine and allopurinol combination therapy is associated with clinical remission in patients with IBD, but its influence on adverse outcomes. In this study Sandra Bohn Thomsen et al. compared patients with IBD treated with thiopurine and allopurinol and patients with IBD treated with thiopurine monotherapy. Click and hear the result.